Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A German registry study found that 12% of ALS patients survive at least 10 years from symptom onset — a figure that matters for care planning. Younger age, slower disease progression, no frontotemporal dementia, and a longer gap between symptoms and diagnosis all predicted better outcomes. The median survival was still just 2.5 years, underscoring the disease's severity.
ALS has long been considered a rapidly fatal disease, but a new German population-based study offers a more nuanced picture. Analyzing data from 200 patients enrolled in a registry in Rhineland-Palatinate between 2009 and 2012, researchers found that while the median survival from symptom onset was 2.5 years, 12% of patients were still alive a decade later — a finding with real implications for long-term care planning.
Not all ALS is created equal. Patients with spinal onset fared significantly better than those with bulbar onset (10-year survival: 14% vs. 3%), and those with the flail limb phenotype had the best outcomes of all (31% 10-year survival). A longer delay between symptom onset and diagnosis was also linked to better survival, likely reflecting a slower-progressing disease course.
By the Numbers:
Why it matters: These findings give clinicians early, accessible prognostic markers — like age, disease phenotype, and progression rate — to better guide patient counseling and advance care planning from the start of the disease journey.
